“Drugs and biologics formulated, packaged and delivered as powders offer tremendous benefits for product stability and can eliminate the need for cold chain management. Our technology provides precision delivery of prescription medications utilizing low cost, mono-dose or multi-dose dispensers without the expense and complexity of volatile propellants,” said
These latest innovations extend the capabilities of Mystic’s VRx2™ “unit of use” packaging and delivery platform enabling the development of new classes of innovative, value-add drug/device combination products and routes of non-invasive administration. VersiDoser® and VRx2™ delivery technologies are used in combination with therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.
Mystic’s delivery platform technologies and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value added, patient-centric products benefits the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical manufacturer. Mystic’s delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.
Mystic Pharmaceuticals® is an integrated specialty pharmaceutical manufacturer based in